Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC)

Abstract

It is still not possible for all patients with early breast cancer to be cured. Even when they respond well to initial therapy, there exists a substantial risk for recurrence, sometimes after several years. With the availability of cyclin-dependent kinase (CDK) 4/6 inhibitors the role of adjuvant therapy has improved, and so has the chance of cure. These consensus guidelines will ensure that the community oncologist will be able to take the right decision for their patient. The expert committee shares their real-world experience as well as the consensus voting results. Patients eligible for adjuvant therapy with CDK4/6 inhibitors should start that treatment at the earliest. Based on current published data, abemaciclib is the preferred CDK4/6 inhibitor that should be used in eligible patients (unless contraindicated). To ensure optimal dose intensity and adherence to treatment schedule, use of literature and patient information material can improves compliance. Treatment modification requires early reporting of adverse effects, a responsibility of the patient and caregiver (relatives).

Keywords

targeted therapy - IDFS - high risk - regulatory approval

Publikationsverlauf

Eingereicht: 13. September 2024

Angenommen: 14. September 2024

Artikel online veröffentlicht:
18. November 2024

• References

• 1 Parikh PM, Bhattacharyya GS, Biswas G. et al. Practical consensus recommendations for optimizing risk versus benefit of chemotherapy in patients with HR positive Her2 negative early breast cancer in India. South Asian J Cancer 2021; 10 (04) 213-219
• 2 Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386 (10001): 1341-1352
• 3 Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 2020; 395 (10226): 817-827
• 4 Ding L, Cao J, Lin W. et al. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci 2020; 21 (06) 1960
• 5 Roskoski Jr R. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacol Res 2019; 139: 471-488
• 6 Cicenas J, Simkus J. CDK inhibitors and FDA: approved and orphan. Cancers (Basel) 2024; 16 (08) 1555
• 7 Xu B. Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy - author's reply. Lancet Oncol 2023; 24 (09) e357
• 8 Johnston SRD, Toi M, O'Shaughnessy J. et al; monarchE Committee Members. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023; 24 (01) 77-90
• 9 Slamon DJ, Stroyakovskiy D, Yardley DA. et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: primary results from the phase III NATALEE trial. J Clin Oncol 2023; 41: LBA500
• 10 Aggarwal S, Vaid A, Ramesh A. et al. Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling. South Asian J Cancer 2018; 7 (02) 96-101
• 11 Parikh P, Babu G, Singh R. et al. Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method. BMC Cancer 2023; 23 (01) 714
• 12 Parikh PM, Hingmire SS, Bhavesh P. et al. Oncology Gold Standard™ consensus statement on counselling patients for molecular testing and personalized cancer care. Int J Mol Immuno Oncol 2017; 2: 47-57
• 13 Parikh PM, Aggarwal S, Biswas G. et al. Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. South Asian J Cancer 2023; 12 (02) 93-99
• 14 Niederberger M, Spranger J. Delphi technique in health sciences: a map. Front Public Health 2020; 8: 457
• 15 Agostinetto E, Arecco L, de Azambuja E. Adjuvant CDK4/6 inhibitors for early breast cancer: how to choose wisely?. Oncol Ther 2024; 12 (01) 19-29
• 16 Johnston SRD, Harbeck N, Hegg R. et al; monarchE Committee Members and Investigators. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 2020; 38 (34) 3987-3998
• 17 Slamon D, Lipatov O, Nowecki Z. et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med 2024; 390 (12) 1080-1091
• 18 Johnston SRD, Toi M, O'Shaughnessy J. et al; monarchE Committee Members. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023; 24 (01) 77-90
• 19 Slamon DJ, Fasching PA, Hurvitz S. et al. Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol 2023 ;15:17588359231178125 Erratum in: Ther Adv Med Oncol. 2023 Sep 29;15:17588359231201818. doi: 10.1177/17588359231201818. PMID: 37275963; PMCID: PMC10233570
• 20 Rastogi P, O'Shaughnessy J, Martin M. et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol 2024; 42 (09) 987-993 Erratum in: J Clin Oncol. 2024 Jun 10;42(17):2111. doi: 10.1200/JCO.24.00711. PMID: 38194616; PMCID: PMC10950161
• 21 Paluch-Shimon S, Neven P, Huober J. et al. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer. Ther Adv Med Oncol 2023 ;15:17588359231151840
• 22 Fasching PA, Hack CC, Nabieva N. et al. Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole. Eur J Cancer 2024; 209: 114239
• 23 Martin M, Hegg R, Kim SB. et al. Treatment with adjuvant abemaciclib plus endocrine therapy in patients with high-risk early breast cancer who received neoadjuvant chemotherapy: a prespecified analysis of the monarchE randomized clinical trial. JAMA Oncol 2022; 8 (08) 1190-1194
• 24 Toi M, Boyle F, Im YH. et al. Adjuvant abemaciclib combined with endocrine therapy: efficacy results in monarchE cohort 1. Oncologist 2023; 28 (01) e77-e81
• 25 Harbeck N, Rastogi P, Martin M. et al; monarchE Committee Members. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2021; 32 (12) 1571-1581
• 26 Rugo HS, O'Shaughnessy J, Boyle F. et al; monarchE Committee Members. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol 2022; 33 (06) 616-627
• 27 Yousuf M, Alam M, Shamsi A. et al. Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: a review on therapeutic implications. Int J Biol Macromol 2022; 218: 394-408
• 28 Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A. CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought. Cancer Cell 2018; 34 (01) 9-20
• 29 Pavlovic D, Niciforovic D, Papic D, Milojevic K, Markovic M. CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review. Ther Adv Med Oncol 2023;15:17588359231205848
• 30 Grinshpun A, Tarantino P. The Evolving Role of CDK4/6 Inhibitors in the Treatment of Advanced and Early-Stage Breast Cancer: Lessons Learned From SONIA and NATALEE. Accessed August 27, 2024 at: https://dailynews.ascopubs.org/do/evolving-role-cdk4-6-inhibitors-treatment-advanced-and-early-stage-breast-cancerst
• 31 Haslam A, Ranganathan S, Prasad V, Olivier T. CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms. Eur J Cancer 2024; 207: 114192
• 32 Ergun Y, Dogan M, Ucar G, Karacin P, Karacin C. Efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive breast cancer: a systematic review and meta-analysis. Expert Opin Pharmacother 2023; 24 (17) 1901-1909
• 33 Tolaney SM, Guarneri V, Seo JH. et al. Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer. Eur J Cancer 2024; 199: 113555
• 34 Goetz MP, Cicin I, Testa L. et al. Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. NPJ Breast Cancer 2024; 10 (01) 34
• 35 Schäffler H, Mergel F, Pfister K. et al. The clinical relevance of the NATALEE study: application of the NATALEE criteria to a real-world cohort from two large German breast cancer centers. Int J Mol Sci 2023; 24 (22) 16366
• 36 Wani K, Patel K, Dabak V. Hepatotoxicity after CDK 4/6 inhibitor initiation in the treatment of hormone-positive metastatic breast cancer. Cureus 2023; 15 (06) e40871
• 37 Korde LA, Somerfield MR, Carey LA. et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 2021; 39 (13) 1485-1505
• 38 Freedman RA, Caswell-Jin JL, Hassett M, Somerfield MR, Giordano SH. Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer Guideline Expert Panel. Optimal adjuvant chemotherapy and targeted therapy for early breast cancer-cyclin-dependent kinase 4 and 6 inhibitors: ASCO guideline rapid recommendation update. J Clin Oncol 2024; 42 (18) 2233-2235
• 39 Leo CP, Hentschel B, Szucs TD, Leo C. FDA and EMA approvals of new breast cancer drugs-a comparative regulatory analysis. Cancers (Basel) 2020; 12 (02) 437
• 40 Parikh PM, Sahoo TP, Biswas G. et al. practical consensus guidelines for the use of S-1 in GI malignancies. South Asian J Cancer 2024; 13 (01) 77-82
• 41 Wander SA, Han HS, Zangardi ML. et al. Clinical outcomes with abemaciclib after prior CDK4/6 inhibitor progression in breast cancer: a multicenter experience. J Natl Compr Canc Netw 2021; •••: 1-8
• 42 Kalinsky K, Accordino MK, Chiuzan C. et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol 2023; 41 (24) 4004-4013
• 43 Gnant M, Dueck AC, Frantal S. et al; PALLAS groups and investigators. Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/AFT-05/BIG-14–03). J Clin Oncol 2022; 40 (03) 282-293
• 44 Loibl S, Marmé F, Martin M. et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer—the penelope-B trial. J Clin Oncol 2021; 39 (14) 1518-1530
• 45 Spring LM, Zangardi ML, Moy B, Bardia A. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist 2017; 22 (09) 1039-1048
• 46 Accessed August 27, 2024 at: https://clinicaltrials.gov/study/NCT04565054
• 47 Accessed August 27, 2024 at: https://clinicaltrials.gov/study/NCT04584853